pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duche
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
delandistrogene moxeparvovec
Phase 3 · gene therapy · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec for Duchenne Muscular Dystrophy is a Phase 3 program (gene_therapy) at Sarepta Therapeutics with 7 ClinicalTrials.gov record(s).
Internal code SRP-9001-303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sarepta Therapeutics
- Phase
- Phase 3
- Modality
- gene_therapy
- Indication
- Duchenne Muscular Dystrophy
- Status
- active
- Trials
- 7